dear editor, Psoriasis is a chronic inflammatory skin disease that affects up to 3% of the
general population worldwide (1). the development of anti-interleukin (iL) drugs has …

Background Tuberculosis has a major global impact. Immunocompetent hosts usually
control this disease, resulting in an asymptomatic latent tuberculosis infection (LTBI) …

Introduction The necessity for tuberculosis preventive treatment (TPT) and routine T-SPOT.
TB monitoring in patients with psoriasis and tuberculosis infection (TBI) undergoing …

Dear Editor, Biologic agents selectively targeting interleukin (IL) 23 represent a
breakthrough in the treatment of patients with moderate–severe psoriasis. 1, 2 Despite …

Over the past 15 years, we have witnessed great advances in the management of moderate
to severe psoriasis. Exploration of pathways of tumour necrosis factor (TNF)–α and …

Psoriasis is an immune-mediated skin disease characterized by an increased inflammatory
response mediated by the IL23/IL17 axis. 1, 2 The latest generation of biologic drugs (ie …

Psoriatic patients with latent tuberculosis infection and properly treated active tuberculosis
need careful management when prescribing modern biological drugs. Although data and …

200 I CUTIS® WWW. MDEDGE. COM/DERMATOLOGY to target specific cytokines
implicated in the disease process and have been increasingly utilized. Tumor necrosis factor …

The interleukin (IL)-12/23 inhibitor ustekinumab has proven to be very efficacious for
psoriasis [1, 2]. In the case of ineffectiveness to ustekinumab, switching to one of the …

The tuberculosis (TB) burden is high in China, with a 32% prevalence of latent tuberculosis
infection (LTBI) in Beijing. Screening for LTBI and the chemoprophylaxis of positive patients …